CAS: 946128-88-7; N-[3-Fluoro-4-[[4-Methyl-2-Oxo-7-(2-Pyrimidinyloxy)-2H-1-Benzopyran-3-Yl]Methyl]-2-Pyridinyl]-N'-Methylsulfamide
该化合物是一个属于小分子类别的化学化合物,主要因其作为某些动脉,特别是癌症信号路径的选择性抑制剂的作用而得到承认;由于药物研究的潜在治疗应用,特别是肿瘤学的应用,因此引起注意;该化合物展示了一种具体的行动机制,针对和调节细胞扩散和生存所涉蛋白的活动,使其成为癌症治疗的候选对象;其化学结构包括一些功能组,这些功能组有助于使其目标动脉具有约束性的亲近性和选择性;此外,对RO51267666进行了有关其药用皮肤特性的研究,包括吸收,分布,新陈代谢和排泄物(ADME),这对于确定临床环境中的功效和安全特征至关重要;与许多调查药物一样,正在进行的研究对于充分了解其生物影响和治疗潜力至关重要.
- 英文名称N-[3-Fluoro-4-[[4-Methyl-2-Oxo-7-(2-Pyrimidinyloxy)-2H-1-Benzopyran-3-Yl]Methyl]-2-Pyridinyl]-N'-Methylsulfamide
- 中文名称RO5126766(CH5126766)抑制剂
- IUPAC名称3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one
- CAS编号946128-88-7
- MFCD编号:MFCD27987901
- FDA UNII编号:D0D4252V97
- 分子式:C21H18FN5O5S分子量:471.47
- 产品CID: 1997778
- 同类组份化合物CAS946128-90-1 (potassium)946128-88-7 (free)946128-89-8 (sodium)
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
- 沸点690.8±65.0 °C(预测)
- 密度1.495±0.06 g/cm3(预测)
- pKa:6.60±0.50(预测)
- 溶解性Insoluble In H2O; Insoluble In Etoh; ≥35.7 mg/mL In DMSO
- 外观形态白色至黄色粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是RAF/MEK双重抑制剂,具有潜在的抗振素活动;它抑制KRAS-色切癌细胞中MEK和ERK的磷酸化作用;诱导BRAFV600E-或NRAS-MUTIMEOMA细胞中G1细胞循环阻塞;在包括HCT116(KRA S-MOTENT),COLO205(BRAFF-MODANT)和SK-MEL-2在内的多种色地磁模型中表现出强大的抗振脉效应;并减少肿瘤基因脱硫中[18F]FDG的吸收,这表明抑制了肿瘤甘蔗代谢.
上下游产品
3-(3-Fluoro-2-Aminopyridin-4-Ylmethyl)-4-Methyl-7-(Pyrimidin-2-Yloxy)-2-Oxo-2H-1-Benzopyran 946126-49-43-(3-Fluoro-2-Aminopyridin-4-Ylmethyl)-7-Hydroxy-4-Methyl-2-Oxo-2H-1-Benzopyran 946127-14-6
合成工艺路线路线简述
- 946126-49-4 + 10438-96-7 = 946128-88-7
反应条件:1.1 Reagents: Pyridine Solvents: Dichloromethane; 4 H,Rt
标题:Preparation Of 2-Oxo-2H-Benzopyran Derivatives And Benzo[e][1,3]Oxazine-2,4-Dione Derivatives As P27 Protein Inducers
参考文献:World Intellectual Property Organization]
946126-49-4 + 10438-96-7 = 946128-88-7
反应条件:1.1 Reagents: Pyridine Solvents: Dimethylformamide; Rt -> 10 °C1.2 Solvents: Acetonitrile; < 5 °C; 90 Min,< 5 °C
标题:Method For Producing Coumarin Derivative
参考文献:World Intellectual Property Organization]
946127-14-6 + 10438-96-7 + 4595-60-2 = 946128-88-7
反应条件:1.1 Reagents: Cesium Carbonate Solvents: Dimethylformamide; 2 H,100 °C1.2 Reagents: Pyridine Solvents: Dimethylformamide,Acetonitrile; -10 °C; 1 H,Rt
标题:Optimizing The Physicochemical Properties Of Raf/mek Inhibitors By Nitrogen Scanning
作者:Aoki,Toshihiro; Hyohdoh,Ikumi; Furuichi,Noriyuki; Ozawa,Sawako; Watanabe,Fumio; Et Al
参考文献:Acs Medicinal Chemistry Letters 日期:2014 卷标:5(4) 页码:309-314]
= 946128-88-7 [标题:Reaction Conditions
标题:Preparation Of The Prodrug Compound And Their Medical Applications
参考文献:World Intellectual Property Organization]
= 946128-88-7 [标题:Reaction Conditions
标题:Preparation Of Coumarin Derivatives As Antitumor Agents
参考文献:World Intellectual Property Organization
📜2-Acetylamino-5-Chloro-3-Fluoropyridine置于哌啶,吡啶,Potassium Carbonate,溶剂黄146,Lithium Hexamethyldisilazane体系中,用 四氢呋喃,2,2,2-三氟乙醇,N,N-二甲基甲酰胺,乙腈 作为反应溶剂,化学反应 21.5H,反应生成 Ro5126766(ch5126766)抑制剂
参考文献:Method For Producing Coumarin Derivative
标题:Method For Producing Coumarin Derivative
海关参考信息
- 2933310010-吡啶
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物
2918290000-其他含酚基羧酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.
专利号:US-2022259212-A1
优先权日:2019-07-11
标题:Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
发明人：BOSS CHRISTOPH; CREN SYLVAINE; KIMMERLIN THIERRY; LOTZ-JENNE CARINA; POTHIER JULIEN; TIDTEN-LUKSCH NAOMI
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in the treatment of inter alia cancer is disclosed.
专利号:US-11267824-B2
优先权日:2017-08-17
标 题:Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
发明人：BOSS CHRISTOPH; BUR DANIEL; CREN SYLVAINE; KIMMERLIN THIERRY; LOTZ-JENNE CARINA; POTHIER JULIEN; TIDTEN-LUKSCH NAOMI
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.
专利号:US-2025011313-A1
优先权日:2021-10-28
标 题:Ccr6 receptor modulators
发明人：ALLEMANN OLIVER; HUBLER FRANCIS; MEYER EMMANUEL
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
专利号:US-2025042881-A1
优先权日:2021-10-26
标 题 :Ccr6 receptor modulators
发明人：ALLEMANN OLIVER; CAROFF EVA; HUBLER FRANCIS; MEYER EMMANUEL
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
专利号:WO-2023057548-A1
优先权日:2021-10-07
标题:Ccr6 receptor modulators
发明人：AISSAOUI HAMED; ALLEMANN OLIVER; CAROFF EVA; MEYER EMMANUEL; RICHARD-BILDSTEIN SYLVIA
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Haider E, Anwar Y, Ekouo J. Avutometinib (Avmapki): oral RAF/MEK clamp inhibitor advancing precision therapy in KRAS-mutant low-grade serous ovarian cancer. Ann Med Surg (Lond). 2025 Dec 15;88(2):2132-2133. doi: 10.1097/MS9.0000000000004586.
2: Ettorre VM, Palmieri L, Ottum S, Greenman M, Santin AD. Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report. Gynecol Oncol Rep. 2025 Dec 17;63:102011. doi: 10.1016/j.gore.2025.102011.
3: Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT- OV60/GOG-3052/RAMP 201. Future Oncol. 2025 Dec;21(30):3859-3871. doi: 10.1080/14796694.2025.2595130. Epub 2025 Dec 12.
合成参考文献
摘要:
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2026).
📝 需求与反馈
尽可能描述清楚需求与问题信息
